Results 11 to 20 of about 1,429,326 (362)
TYROSINE KINASE INHIBITORS AND INTERFERON
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj +4 more sources
TYROSINE KINASE INHIBITORS AND PREGNANCY
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese +3 more
doaj +5 more sources
The SYK tyrosine kinase: a crucial player in diverse biological functions
Nature Reviews Immunology, 2010 Attila Mócsai +2 more
exaly +2 more sources
Targeting Bruton's tyrosine kinase in B cell malignancies
Nature Reviews Cancer, 2014 Rudi W Hendriks, Saravanan Y Pillai
exaly +2 more sources
Thoracic Cancer, 2021 Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura +12 more
doaj +1 more source
mTORC2 is a tyrosine kinase [PDF]
Cell Research, 2015 The mammalian target of rapamycin (mTOR), a protein kinase, is the centre of huge attention due to its importance in intracellular signaling and in health and disease. In their recent study, Yin et al. show that mTOR can regulate signaling through the insulin-like growth factor 1 receptor and that it possesses a new enzymatic activity - the ability to ...
Christopher G. Proud, Xuemin Wang
openaire +2 more sources
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Journal of Hematology & Oncology, 2020 Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then ...
Liling Huang, Shiyu Jiang, Yuankai Shi
semanticscholar +1 more source
Cancer Treatment and Research Communications, 2021 Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi +2 more
doaj +1 more source
Tyrosine Kinase Receptors in Oncology [PDF]
International Journal of Molecular Sciences, 2020 Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development.
Jorge Esteban-Villarrubia +8 more
openaire +4 more sources
The tyrosine kinase Csk dimerizes through Its SH3 domain. [PDF]
PLoS ONE, 2009 The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic
Nicholas M Levinson +2 more
doaj +1 more source